$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying

Author: Avi Kapoor | February 28, 2024 10:06am

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

V.F. Corporation

• The Trade: V.F. Corporation (NYSE:VFC) Director Richard Carucci acquired a total of 20,000 shares an average price of $15.53. To acquire these shares, it cost around $310,620.
• What’s Happening: VF Corp expanded board with appointment of Caroline Brown following engagement with Engaged Capital.
• What V.F. Corporation Does: VF designs, produces, and distributes branded apparel, footwear, and accessories.

Western Midstream Partners

• The Trade: Western Midstream Partners, LP (NYSE:WES) Director Kenneth F. Owen acquired a total of 7,000 shares at an average price of $33.96. To acquire these shares, it cost around $237,720.
• What’s Happening: On Feb. 21, Western Midstream Partners reported a year-over-year increase in fourth-quarter revenue results.
• What Western Midstream Partners Does: Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets.

Don’t forget to check out our premarket coverage here

Ocular Therapeutix

• The Trade: Ocular Therapeutix, Inc. (NASDAQ:OCUL) 10% owner Summer Road LLC bought a total of 930,851 shares at an average price of $7.52. To acquire these shares, it cost around 7 million.
• What’s Happening: On Feb. 22, Ocular Therapeutix announced a $325 million private placement.
• What Ocular Therapeutix Does: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye.

 

Check This Out: Investor Sentiment Improves Following Economic Reports; S&P 500 Settles Higher

 

Posted In: OCUL VFC WES